The claim running through this Ankur Capital panel is that India's deep-science problem is an input problem. Renuka's case for BioPrime Agri is that every agricultural input the country uses — the fertiliser chemistry, the micronutrients, the pesticides — was designed somewhere else and merely manufactured here, for farms nothing like ours; fertiliser use efficiency sits around 20%, so four-fifths of what a farmer buys locks into the soil or washes into a river, subsidised out of the taxpayer's pocket. Deepak's case for Morphing Machines is the silicon mirror image: a $42 billion annual chip import bill on which India captures only 10–20% of the margin, a category-3 listing that caps advanced GPU shipments at 4,000 a year against the 12,000 one data centre needs, and the $20 billion team-and-licence deal he says Nvidia used to absorb Groq without an antitrust review. Both argue the fix is not a better lab but a tighter chain — design, a Tata foundry, domestic packaging, EMS integrators willing to put an Indian part in the bill of materials — plus the discipline neither ecosystem has yet: productisation, and the first sale. The hardest sell, they agree, is domestic belief. Renuka had to talk her own team out of wishing the technology were Australian before she could face a farmer with it. With roughly $25 billion of data-centre capex landing and 90,000 patents filed in 2024, the open question is whether India captures that value or assembles somebody else's.
Worth your time if you are
Chip founders weighing an India-first beachhead
Agri-input and biotech founders scaling out of a lab
Policy people designing India's deep-tech schemes
Investors sizing India's semiconductor value capture
Students trying to fund a first tape-out